Dare Bioscience News

Brookline Capital Upgrades Dare Bioscience, Cites Improved Funding

Seeking AlphaMay 16 01:54

Brookline Capital: Upgraded Dare Bioscience (DARE.US) rating from holding to buying, with a target price of $3.00.

Brookline Capital: Upgraded Dare Bioscience (DARE.US) rating from holding to buying, with a target price of $3.00.

Zhitong FinanceMay 15 18:27

Brookline Capital Upgrades Dare Bioscience to Buy, Announces $3 Price Target

Brookline Capital analyst Kemp Dolliver upgrades Dare Bioscience from Hold to Buy and announces $3 price target.

Analyst UpgradesMay 15 18:13

Earnings Call Summary | Dare Bioscience(DARE.US) Q1 2024 Earnings Conference

The following is a summary of the Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript:Financial Performance:Dare reported Q1 2024 general and administrative expenses of approximately $2.7 m

Futu NewsMay 15 11:00 · Conference Call

Dare Bioscience | 10-Q: Quarterly report

SEC announcementMay 15 04:09 · Announcements

Dare Bioscience Q1 EPS $(0.07) Misses $(0.06) Estimate

Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 22.22 percent increase over losses of $(

BenzingaMay 14 20:27

Earnings Flash (DARE) DARE BIOSCIENCE Posts Q1 Revenue $9,302

08:03 AM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (DARE) DARE BIOSCIENCE Posts Q1 Revenue $9,302

MT NewswiresMay 14 20:03

Dare Bioscience 1Q Loss/Shr 7c >DARE

Dare Bioscience 1Q Loss/Shr 7c >DARE

Dow JonesMay 14 20:00

Press Release: Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milest

Dow JonesMay 14 20:00

Dare Bioscience Files For Common Stock Offering Of Up To $18.1M

Dare Bioscience Files For Common Stock Offering Of Up To $18.1M

BenzingaMay 11 04:31

Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30

GlobeNewswireMay 7 20:00

Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Shares of H&E Equipment Services, Inc. (NASDAQ:HEES) fell sharply during Tuesday's session following mixed first-quarter results.H&E Equipment posted GAAP earnings of 71 cents per share, versus market

BenzingaMay 1 01:24

Xoma Has Acquired An Economic Interest In Three Women's Health Assets From Daré Bioscience For An Upfront Payment Of $22M

Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023.XOMA further expands its late-stage portfolio with synthetic royalty and milestone i

BenzingaApr 30 19:36

Press Release: Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates Through Key Catalysts

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts $22 million of non-diluti

Dow JonesApr 30 19:30

12 Health Care Stocks Moving In Wednesday's After-Market Session

GainersAcrivon Therapeutics (NASDAQ:ACRV) stock rose 12.3% to $10.67 during Wednesday's after-market session. The market value of their outstanding shares is at $329.4 million. Amarin Corp (NASDAQ:AMR

BenzingaApr 25 04:31

Press Release: Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 Dare Bioscience's DARE-LARC1 Platform Technology has Transformative Po

Dow JonesApr 23 20:00

Dare Bioscience Cut to Hold From Buy by Brookline Capital

Dare Bioscience Cut to Hold From Buy by Brookline Capital

Dow JonesApr 18 01:38

Brookline Capital: Downgraded Dare Bioscience (DARE.US) rating from buy to hold.

Brookline Capital: Downgraded Dare Bioscience (DARE.US) rating from buy to hold.

Zhitong FinanceApr 18 01:30

Brookline Capital Downgrades Dare Bioscience to Hold

Brookline Capital analyst Kemp Dolliver downgrades Dare Bioscience (NASDAQ:DARE) from Buy to Hold.

BenzingaApr 18 01:28

Daré Bioscience Announces Publication In Contraception Of Efficacy And Safety Findings From A Pre-Pivotal Postcoital Test Study Of Ovaprene: An Investigational Hormone-Free Monthly Intravaginal Contraceptive

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 womenPivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrollingOvaprene has the po

BenzingaApr 11 20:15